The efficiency of Pfizer BioNTechThe Covid-19 anti-infective vaccine fell precipitously over several months. The number of cases dropped to 47% from 88% one month after the first shot series, according to an observational report published in The Lancet.

While the two-dose mRNA vaccine’s efficacy against infection wanes, its protection against Covid-related hospitalizations persists, remaining 90% effective for all coronavirus variants of concern — including delta — for at least six months, according to the study, which was funded by Pfizer.

This confirms early reports of Israeli health officials and the Centers for Disease Control and Prevention that indicated the effectiveness of keeping patients out the hospital was not affected by infection protection.

According to Dr. Sara Tartof (an epidemiologist at Kaiser Permanente, and lead author of the study), “Protection against infections does decrease in the following months after a second dosage.” Kaiser Permanente carried out the research in collaboration with Pfizer.

This data is published less than 2 weeks after U.S. regulators granted approval to distribute booster shots of Pfizer BioNTech vaccine. array of AmericansAll ages, even those who are considered at highest risk. The eligibility for Pfizer boosters is limited to those who received the vaccines originally. The policy, which will provide third Pfizer doses for 60 million people (and 20 million who were eligible immediately), President Joe Biden announced late last month.

Two-day meeting of a critical advisory group to the Food and Drug Administration is planned for next week. The purpose of this meeting will be to determine whether or not health regulators should make recommendations about booster shots being given to people who have already received these drugs. ModernaOr Johnson & Johnson’s vaccines.

Booster shots have been a contentious topic for scientists — in and outside the government — especially as many people in the U.S. and other parts of the world have yet to receive even one dose of a vaccine.

On Monday evening, the Kaiser Permanente Southern California health care system analyzed more than 3 million electronic records. These data were collected from Dec. 4 through Aug. 8. The proportion of positive patients attributed the the delta variant to increased during the period under study, going from 0.6% to 87% in April to just over 87% in July.

Pfizer’s vaccine was effective against Delta variant infections at 93% for a month following the first dose. It fell to 53% after four months. According to the study, 97% effectiveness was achieved against delta variant infections after one month. This decreased to 67% four months later.

Researchers reported that the effectiveness against hospitalizations due to the delta was 93% throughout the entire study period.

Dr. Luis Jodar from Pfizer, Pfizer’s chief medical officer for vaccinations said that the decrease in effectiveness for infections is likely to be due to “waning” and not because of vaccine protection evasion.

He stated that “our variant-specific analysis clearly showed that the BNT162b2 vaccination is effective against all current varieties of concern including delta” in a press release released alongside the study.